Teva Study Examines Treatment Selection in Schizophrenia
Tel Aviv, Israel, September 18, 2026 Teva Pharmaceuticals has announced new findings from a study examining the factors that...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Tel Aviv, Israel, September 18, 2026 Teva Pharmaceuticals has announced new findings from a study examining the factors that...
PARSIPPANY, N.J., and TEL AVIV, Israel, August 31, 2026 Teva Pharmaceuticals announced a shared commitment with the Trump Administration...
PARSIPPANY, N.J., August 19, 2026 Teva Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its...
PARSIPPANY, New Jersey, USA & TEL AVIV, Israel – June 8, 2026 Teva Pharmaceuticals has unveiled new real-world and...
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals announced new real-world data demonstrating that treatment with...
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals has presented new real-world evidence demonstrating that treatment...
TEL AVIV, Israel & PARIS, May 21, 2026 Teva Pharmaceuticals and Medincell have announced that the European Medicines Agency...
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 Teva Pharmaceuticals has announced new findings from its ongoing IMPACT-TD...
